Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAREFNDR trial of paltusotine for carcinoid syndrome
2024-519875-24-00Phase 3Authorised
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Syndrome (CS) comparing Paltusotine with Placebo (2 arms). Primary endpoint: Change in flushing episodes per day. Planned start Sep 2025; status: authorised.
02
Drugs
paltusotine
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on 2024-519875-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519875-24-00.